“Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials”, J of Skin, vol. 9, no. 2, p. s532, Mar. 2025, doi: 10.25251/skin.10.supp.532.